References
- Kozaki S. Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1979;308:67–70.
- Chenwang D, Shiwei B, Dashan Y, Qiang L, Bin C, Muxin Z, Pengcheng L, Senkai L. Application of botulinum toxin type A in myocutaneous flap expansion. Plast Reconstr Surg. 2009;124:1450–1457.
- Kim TK, Oh EJ, Chung JY, Park JW, Cho BC, Chung HY. The effects of botulinum toxin A on the survival of a random cutaneous flap. J Plast Reconstr Aesthet Surg. 2009;62:906–913.
- Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365:160–163.
- Flynn TC, Clark RE II. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg. 2003;29:519–522; discussion 22.
- Carruthers A, Carruthers J, Flynn TC, Leong MS. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg. 2007;33:S60–S68.
- Spencer JM, Gordon M, Goldberg DJ. Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther. 2002;4:19–23.
- Yamauchi PS, Lowe NJ. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol. 2004;22:34–39.
- Hatheway CH, Dang C. Immunogenicity of the neurotoxins of Clostridium botulinum. In: Jankovic J, Hallett M, editors. Therapy With Botulinum Toxin. New York, NY; 1994. p. 93–107.
- Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–217.
- Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743–1746.